<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Hepatic <z:chebi fb="0" ids="17855">triglyceride</z:chebi> is closely associated with hepatic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and is known to be decreased by thiazolididinediones </plain></SENT>
<SENT sid="1" pm="."><plain>We studied the effect of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> on hepatic <z:chebi fb="0" ids="17855">triglyceride</z:chebi> content and the consequent effect on postprandial endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> production (EGP) in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: Ten subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> on <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> therapy were treated with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (30 mg daily) for 16 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>EGP was measured using a dynamic isotopic methodology after a standard liquid test meal both before and after <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Liver and muscle <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels were measured by (1)H magnetic resonance spectroscopy, and intra-abdominal fat content was measured by magnetic resonance imaging </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> treatment reduced mean plasma fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> and mean peak postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> levels </plain></SENT>
<SENT sid="6" pm="."><plain>Fasting EGP decreased after <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> treatment (16.6 +/- 1.0 vs. 12.2 +/- 0.7 micromol  </plain></SENT>
<SENT sid="7" pm="."><plain>kg(-1)  </plain></SENT>
<SENT sid="8" pm="."><plain>min(-1), P = 0.005) </plain></SENT>
<SENT sid="9" pm="."><plain>Between 80 and 260 min postprandially, EGP was twofold lower on <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (2.58 +/- 0.25 vs. 1.26 +/- 0.30 micromol  </plain></SENT>
<SENT sid="10" pm="."><plain>kg(-1)  </plain></SENT>
<SENT sid="11" pm="."><plain>min(-1), P &lt; 0.001) </plain></SENT>
<SENT sid="12" pm="."><plain>Hepatic <z:chebi fb="0" ids="17855">triglyceride</z:chebi> content decreased by approximately 50% (P = 0.03), and muscle (anterior tibialis) <z:chebi fb="0" ids="17855">triglyceride</z:chebi> content decreased by approximately 55% (P = 0.02) </plain></SENT>
<SENT sid="13" pm="."><plain>Hepatic <z:chebi fb="0" ids="17855">triglyceride</z:chebi> content was directly correlated with fasting EGP (r = 0.64, P = 0.01) and inversely correlated to percentage suppression of EGP (time 150 min, r = -0.63, P = 0.02) </plain></SENT>
<SENT sid="14" pm="."><plain>Muscle <z:chebi fb="0" ids="17855">triglyceride</z:chebi>, subcutaneous fat, and visceral fat content were not related to EGP </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSIONS Reduction in hepatic <z:chebi fb="0" ids="17855">triglyceride</z:chebi> by <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> is very closely related to improvement in fasting and postprandial EGP in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>